Logo

10x Genomics: Kim Popovits

Apr 02, 2020

10x Genomics has appointed Kim Popovits to its board of directors. Popovits is the former chairman, president, and CEO of Genomic Health. She started at Genomic Health in 2002 as president and chief operating officer, before becoming CEO in 2009 and chairman in 2012. The company was acquired by Exact Sciences in November 2019.

Prior to joining Genomic Health, Popovits held several management roles at Genentech, including senior vice president of marketing and sales where she led the commercialization of 14 new therapies. In addition to her board position at 10x Genomics, Popovits is currently a member of the boards of Kiniksa Pharmaceuticals and MyoKardia, and previously served on the board of ZS Pharma.  

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.